358 related articles for article (PubMed ID: 1719549)
1. Pharmacological properties of a potent and selective nonpeptide substance P antagonist.
Garret C; Carruette A; Fardin V; Moussaoui S; Peyronel JF; Blanchard JC; Laduron PM
Proc Natl Acad Sci U S A; 1991 Nov; 88(22):10208-12. PubMed ID: 1719549
[TBL] [Abstract][Full Text] [Related]
2. Comparison in different tissue preparations of the in vitro pharmacological profile of RP 67580, a new non-peptide substance P antagonist.
Carruette A; Moussaoui SM; Champion A; Cottez D; Goniot P; Garret C
Neuropeptides; 1992 Dec; 23(4):245-50. PubMed ID: 1282222
[TBL] [Abstract][Full Text] [Related]
3. [RP 67580, a potent and selective substance P non-peptide antagonist].
Garret C; Carruette A; Fardin V; Moussaoui S; Peyronel JF; Blanchard JC; Laduron PM
C R Acad Sci III; 1992; 314(5):199-204. PubMed ID: 1376187
[TBL] [Abstract][Full Text] [Related]
4. A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically.
Moussaoui SM; Montier F; Carruette A; Blanchard JC; Laduron PM; Garret C
Br J Pharmacol; 1993 May; 109(1):259-64. PubMed ID: 7684305
[TBL] [Abstract][Full Text] [Related]
5. FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.
Morimoto H; Murai M; Maeda Y; Hagiwara D; Miyake H; Matsuo M; Fujii T
Br J Pharmacol; 1992 May; 106(1):123-6. PubMed ID: 1380378
[TBL] [Abstract][Full Text] [Related]
6. FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity.
Morimoto H; Murai M; Maeda Y; Yamaoka M; Nishikawa M; Kiyotoh S; Fujii T
J Pharmacol Exp Ther; 1992 Jul; 262(1):398-402. PubMed ID: 1378096
[TBL] [Abstract][Full Text] [Related]
7. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.
Beaujouan JC; Heuillet E; Petitet F; Saffroy M; Torrens Y; Glowinski J
Br J Pharmacol; 1993 Mar; 108(3):793-800. PubMed ID: 7682138
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of substance P and related peptides by RP 67580 and CP-96,345, at tachykinin NK1 receptor sites, in the rat urinary bladder.
Montier F; Carruette A; Moussaoui S; Boccio D; Garret C
Eur J Pharmacol; 1994 Jan; 251(1):9-14. PubMed ID: 7511108
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888.
Fujii T; Murai M; Morimoto H; Maeda Y; Yamaoka M; Hagiwara D; Miyake H; Ikari N; Matsuo M
Br J Pharmacol; 1992 Nov; 107(3):785-9. PubMed ID: 1282073
[TBL] [Abstract][Full Text] [Related]
10. Tachykinin receptors in smooth muscles: a study with agonists (substance P, neurokinin A) and antagonists.
Mizrahi J; Dion S; D'Orléans-Juste P; Escher E; Drapeau G; Regoli D
Eur J Pharmacol; 1985 Nov; 118(1-2):25-36. PubMed ID: 2417867
[TBL] [Abstract][Full Text] [Related]
11. WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity.
Oleynek JJ; Sedlock DM; Barrow CJ; Appell KC; Casiano F; Haycock D; Ward SJ; Kaplita P; Gillum AM
J Antibiot (Tokyo); 1994 Apr; 47(4):399-410. PubMed ID: 7515038
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
[TBL] [Abstract][Full Text] [Related]
13. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
14. The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.
Guard S; Boyle SJ; Tang KW; Watling KJ; McKnight AT; Woodruff GN
Br J Pharmacol; 1993 Sep; 110(1):385-91. PubMed ID: 7693284
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.
Emonds-Alt X; Doutremepuich JD; Heaulme M; Neliat G; Santucci V; Steinberg R; Vilain P; Bichon D; Ducoux JP; Proietto V
Eur J Pharmacol; 1993 Dec; 250(3):403-13. PubMed ID: 7509286
[TBL] [Abstract][Full Text] [Related]
17. Activity of peptide and non-peptide antagonists at peripheral NK1 receptors.
Patacchini R; Santicioli P; Astolfi M; Rovero P; Viti G; Maggi CA
Eur J Pharmacol; 1992 Apr; 215(1):93-8. PubMed ID: 1381319
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
19. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
20. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P.
Pradier L; Ménager J; Le Guern J; Bock MD; Heuillet E; Fardin V; Garret C; Doble A; Mayaux JF
Mol Pharmacol; 1994 Feb; 45(2):287-93. PubMed ID: 7509440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
